Sugi Predict

Sugi Predict / Targets / TRPM4

TRPM4

Transient receptor potential cation channel subfamily M member 4 · Q8TD43 · TRPM4 on Sugi Atlas →

4,926 patent compounds predicted against TRPM4, 3,232 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3258564 SCHEMBL3258564 0.51 8/20
SCHEMBL3556584 SCHEMBL3556584 0.51 6/20
SCHEMBL471068 SCHEMBL471068 0.36 5/20
SCHEMBL3030809 SCHEMBL3030809 0.43 4/20
SCHEMBL2274054 SCHEMBL2274054 0.56 3/20
SCHEMBL2635480 SCHEMBL2635480 0.55 3/20
SCHEMBL2271116 SCHEMBL2271116 0.52 3/20
SCHEMBL2635491 SCHEMBL2635491 0.49 3/20
SCHEMBL3555635 SCHEMBL3555635 0.48 3/20
SCHEMBL2635583 SCHEMBL2635583 0.47 3/20
SCHEMBL2636056 SCHEMBL2636056 0.47 3/20
SCHEMBL2635646 SCHEMBL2635646 0.46 3/20
SCHEMBL3556271 SCHEMBL3556271 0.44 3/20
SCHEMBL2635974 SCHEMBL2635974 0.43 3/20
SCHEMBL1223406 SCHEMBL1223406 0.36 3/20
SCHEMBL3347355 SCHEMBL3347355 0.33 3/20
SCHEMBL1308597 SCHEMBL1308597 0.61 2/20
SCHEMBL1307810 SCHEMBL1307810 0.58 2/20
SCHEMBL417813 SCHEMBL417813 0.56 2/20
SCHEMBL2635561 SCHEMBL2635561 0.56 2/20

Clinical trials — most relevant to TRPM4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) PHASE4COMPLETED
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls PHASE4COMPLETED
Switching From Restasis to TRYPTYR PHASE4NOT_YET_RECRUITING
Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) PHASE4NOT_YET_RECRUITING
The Re-Prosper HF Study PHASE2/PHASE3COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC PHASE1COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases PHASE1COMPLETED
Do Acid Sensing Ion Channels Contribute to Heartburn? PHASE1COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 EARLY_PHASE1COMPLETED
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3 EARLY_PHASE1COMPLETED
Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1 EARLY_PHASE1RECRUITING
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. nanCOMPLETED
The Natural History of TRPV4 Neuropathy nanRECRUITING
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Effects of an Anti-TRPM8 in the Atopic Dermatitis Pruritus nanCOMPLETED
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients nanACTIVE_NOT_RECRUITING
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Dissecting the Heterogeneity of Oral Cancer Pain nanUNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis nanUNKNOWN
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures nanCOMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis nanUNKNOWN
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin nanENROLLING_BY_INVITATION
Investigation of the Pruritogens of Liver-related Diseases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TRPM4 binder may also engage these)

ProteinNameSimilarity
Q7TN37 — 0.996 Q7TN37 →
Q9ESQ5 — 0.994 Q9ESQ5 →
Q9JJH7 — 0.981 Q9JJH7 →
TRPM5 Transient receptor potential cation channel subfamily M member 5 0.979 landscape →
Q9R283 — 0.974 Q9R283 →
S5UH55 — 0.973 S5UH55 →
A0A0R4IMY7 — 0.973 A0A0R4IMY7 →
P70268 — 0.971 P70268 →
P47823 — 0.971 P47823 →
EIF2B5 Translation initiation factor eIF2B subunit epsilon 0.971 landscape →
O89109 — 0.970 O89109 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.970 landscape →
GPAA1 GPI-anchor transamidase component GPAA1 0.969 landscape →
A1A4I4 — 0.969 A1A4I4 →
Q8CHW4 — 0.968 Q8CHW4 →
NOX5 NADPH oxidase 5 0.968 landscape →
Q8BMQ8 — 0.967 Q8BMQ8 →
Q9Z2G1 — 0.967 Q9Z2G1 →
Q5GH72 — 0.967 Q5GH72 →
Q17RQ9 — 0.967 Q17RQ9 →
KCNN4 Intermediate conductance calcium-activated potassium channel protein 4 0.967 landscape →
P70295 — 0.967 P70295 →
Q8ND23 — 0.967 Q8ND23 →
Q0VF94 — 0.966 Q0VF94 →
Q9R244 — 0.966 Q9R244 →
Q61161 — 0.966 Q61161 →
Q29RM5 — 0.966 Q29RM5 →
Q32NY4 — 0.966 Q32NY4 →
HDAC10 Polyamine deacetylase HDAC10 0.965 landscape →
Q6ZT62 — 0.965 Q6ZT62 →